Blue Ridge

Blue Ridge Biopharma is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the development of mRNA-based vaccines and therapeutics. The company leverages a proprietary mRNA-LNP (lipid nanoparticle) platform to design highly potent and stable candidates for infectious diseases and oncology. Its lead program, BRB-001, is an mRNA vaccine for COVID-19 that has demonstrated promising safety and immunogenicity in clinical trials. Beyond COVID-19, Blue Ridge is advancing a diverse pipeline that includes a next-generation rabies vaccine and various cancer immunotherapy programs. The company aims to establish itself as a leader in the global mRNA landscape by optimizing delivery technologies and rapid manufacturing processes.